Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Acorda Therapeutics price target raised to $35 from $5 at Cowen » 13:59
01/13/21
01/13
13:59
01/13/21
13:59
ACOR

Acorda Therapeutics

$5.96 /

+1.7 (+39.91%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau raised the firm's price target on Acorda Therapeutics to $35 from $5 and keeps an Outperform rating on the shares after the company announced the sale of its manufacturing operations and a 16% headcount reduction. The sale and restructuring will net $70M in cash and yield $40M of annualized cost savings, "meaningfully increasing the likelihood" that the company can fund operations back to profitability, said Nadeau.

ShowHide Related Items >><<
ACOR Acorda Therapeutics
$5.96 /

+1.7 (+39.91%)

ACOR Acorda Therapeutics
$5.96 /

+1.7 (+39.91%)

ACOR Acorda Therapeutics
$5.96 /

+1.7 (+39.91%)

ACOR Acorda Therapeutics
$5.96 /

+1.7 (+39.91%)

Hot Stocks
Catalent to acquire manufacturing operations from Acorda Therapeutics » 09:59
01/13/21
01/13
09:59
01/13/21
09:59
CTLT

Catalent

$116.00 /

+0.215 (+0.19%)

, ACOR

Acorda Therapeutics

$6.62 /

+2.36 (+55.40%)

Catalent (CTLT) announced…

Catalent (CTLT) announced it has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics (ACOR). The acquisition complements Catalent's status as a premier U.S.-based partner for companies across dry powder inhaled dose forms. Completion of the transaction is subject to customary closing conditions and is expected to occur in the first quarter of this calendar year. Under the terms of the agreement, Catalent will acquire Acorda Therapeutics' 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, close to Boston Logan International Airport and the thriving biotechnology networks centered around Boston and Cambridge. The site operates best-in-class spray drying capacity, including GEA NIRO PSD-1, PSD-4 and PSD-7 spray drying units, with the latter unit being the largest equipment of its kind in North America, and will provide Catalent with significant commercial-scale capacity for new customer programs. The facility will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging. On closing, Acorda Therapeutics' current workforce at the facility will transition employment to Catalent. Catalent has also entered into a long-term supply agreement with Acorda Therapeutics to continue commercial manufacture of INBRIJA from the Chelsea facility. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine. The Chelsea site will complement and provide downstream capabilities to Catalent's 180,000 square-foot inhalation development facility in Morrisville, Research Triangle Park, North Carolina, which includes development and manufacturing for metered dose inhalers, nasal sprays, and dry powder inhalers. The Morrisville site offers high-speed commercial-scale manufacturing as well as flexible fill lines for clinical-scale and small batch production.

ShowHide Related Items >><<
CTLT Catalent
$116.00 /

+0.215 (+0.19%)

ACOR Acorda Therapeutics
$6.62 /

+2.36 (+55.40%)

CTLT Catalent
$116.00 /

+0.215 (+0.19%)

01/08/21 JPMorgan
Catalent price target raised to $130 from $110 at JPMorgan
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/09/20 KeyBanc
Catalent upgraded to Overweight upon assumption at KeyBanc
12/09/20 KeyBanc
Catalent upgraded to Overweight from Sector Weight at KeyBanc
ACOR Acorda Therapeutics
$6.62 /

+2.36 (+55.40%)

CTLT Catalent
$116.00 /

+0.215 (+0.19%)

ACOR Acorda Therapeutics
$6.62 /

+2.36 (+55.40%)

  • 23
    Nov
  • 11
    Jun
  • 04
    Feb
CTLT Catalent
$116.00 /

+0.215 (+0.19%)

ACOR Acorda Therapeutics
$6.62 /

+2.36 (+55.40%)

ACOR Acorda Therapeutics
$6.62 /

+2.36 (+55.40%)

Hot Stocks
Acorda Therapeutics sees Q4 Inbrija net revenue of $9M, Ampyra sales of $25M » 09:11
01/13/21
01/13
09:11
01/13/21
09:11
ACOR

Acorda Therapeutics

$4.25 /

+0.12 (+2.91%)

Accorda said earlier that…

Accorda said earlier that it forecasts INBRIJA Q4 2020 net revenue of approximately $9M and full year 2020 net revenue of approximately $24M. Accorda sees AMPYRA ER Tablets, 10 mg net revenue for Q4 2020 of approximately $25M and FY20 net revenue of approximately $98M. The company continues to expect full year non-GAAP 2020 operating expense of $170M-$180M and sees 2020 year-end cash, cash equivalents and restricted cash were approximately $102M. Acorda expects that combined savings from the sale, restructuring and other operating cost reductions will reduce annual operating expenses by approximately $40M. The company provided new operating expense guidance of $130M-$140M for the full year 2021.

ShowHide Related Items >><<
ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

Syndicate
Acorda Therapeutics announces 'at the market' offering agreement » 09:08
01/13/21
01/13
09:08
01/13/21
09:08
ACOR

Acorda Therapeutics

$4.25 /

+0.12 (+2.91%)

Acorda announced it…

Acorda announced it entered into an At The Market Offering Agreement with H.C. Wainwright & Co. as sales agent. Pursuant to the ATM Agreement, the company may offer and sell shares of its common stock having an aggregate value of up to $15.25M in an at-the-market offering. The shares of common stock will be offered pursuant to the company's effective Registration Statement on Form S-3, which was declared effective by the Securities and Exchange Commission on September 17, 2020.

ShowHide Related Items >><<
ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

Hot Stocks
Acorda Therapeutics announces corporate restructuring » 09:07
01/13/21
01/13
09:07
01/13/21
09:07
ACOR

Acorda Therapeutics

$4.25 /

+0.12 (+2.91%)

Acorda Therapeutics…

Acorda Therapeutics announced a corporate restructuring to reduce costs and focus its resources on INBRIJA. In addition to the associates who will transition to Catalent, Acorda is reducing its combined Ardsley, Waltham and field headcount by approximately 16% through a reduction in force. "Today's announcements represent important steps in our ongoing efforts to strengthen our capital structure, enhance our operating efficiency and position Acorda to drive long-term value for our shareholders," said Ron Cohen, M.D., Acorda's President and CEO. "Through the sale of the Chelsea operations we are monetizing our excess manufacturing capacity and significantly reducing expenses. This will ensure that our patients have uninterrupted access to INBRIJA, while meaningfully improving both our balance sheet and P&L. The restructuring is necessary for Acorda to have an infrastructure and expenses that are right-sized for our products and revenue. This is a difficult step for us all, not least for those who will no longer be employed at the company. We thank them for their dedication and contributions in bringing INBRIJA and AMPYRA to the patient communities we serve. We will be providing these colleagues with severance and assistance in seeking new positions," he added.

ShowHide Related Items >><<
ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

Hot Stocks
Acorda to sell Inbrija manufacturing operations to Catalent for $80M » 09:05
01/13/21
01/13
09:05
01/13/21
09:05
ACOR

Acorda Therapeutics

$4.25 /

+0.12 (+2.91%)

, CTLT

Catalent

$115.79 /

+0.37 (+0.32%)

Acorda Therapeutics…

Acorda Therapeutics (ACOR) announced that it has entered into a definitive agreement to sell its Inbrija manufacturing operations in Chelsea, Massachusetts to Catalent (CTLT) for $80M in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package Inbrija for Acorda, ensuring an uninterrupted drug supply for Acorda's patients and continued adherence to best-in-class manufacturing quality and safety standards. As part of the deal, Catalent will absorb all Acorda employees who work at the Chelsea facility, and certain Acorda employees at the Company's Waltham, Massachusetts facility.

ShowHide Related Items >><<
CTLT Catalent
$115.79 /

+0.37 (+0.32%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

CTLT Catalent
$115.79 /

+0.37 (+0.32%)

01/08/21 JPMorgan
Catalent price target raised to $130 from $110 at JPMorgan
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/09/20 KeyBanc
Catalent upgraded to Overweight upon assumption at KeyBanc
12/09/20 KeyBanc
Catalent upgraded to Overweight from Sector Weight at KeyBanc
CTLT Catalent
$115.79 /

+0.37 (+0.32%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

  • 23
    Nov
  • 11
    Jun
  • 04
    Feb
CTLT Catalent
$115.79 /

+0.37 (+0.32%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

ACOR Acorda Therapeutics
$4.25 /

+0.12 (+2.91%)

Hot Stocks
Acorda Therapeutics completes 1-for-6 reverse stock split » 16:20
12/31/20
12/31
16:20
12/31/20
16:20
ACOR

Acorda Therapeutics

$0.69 /

-0.016 (-2.26%)

Acorda Therapeutics…

Acorda Therapeutics announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the company's common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021. The reverse stock split was effected in accordance with the authorization adopted by Acorda's stockholders at the company's Special Meeting of Stockholders held on July 31, 2020. The reverse stock split is intended to enable the company to regain compliance with the $1.00 per share minimum bid price required for continued listing on The Nasdaq Global Select Market.

ShowHide Related Items >><<
ACOR Acorda Therapeutics
$0.69 /

-0.016 (-2.26%)

ACOR Acorda Therapeutics
$0.69 /

-0.016 (-2.26%)

ACOR Acorda Therapeutics
$0.69 /

-0.016 (-2.26%)

ACOR Acorda Therapeutics
$0.69 /

-0.016 (-2.26%)

Over a month ago
Options
Largest borrow rate increases among liquid names » 08:45
11/16/20
11/16
08:45
11/16/20
08:45
BIGC

BigCommerce

$66.87 /

-6.3 (-8.61%)

, CGC

Canopy Growth

$24.43 /

+0.61 (+2.56%)

, MVIS

MicroVision

$1.85 /

-0.005 (-0.27%)

, TRIL

Trillium Therapeutics

$15.50 /

+1.44 (+10.24%)

, APRN

Blue Apron

$5.58 /

+0.015 (+0.27%)

, NEPT

Neptune Wellness

$1.86 /

-0.01 (-0.53%)

, APHA

Aphria

$5.68 /

+0.255 (+4.70%)

, HEXO

Hexo

$0.74 /

-0.0002 (-0.03%)

, ACOR

Acorda Therapeutics

$0.83 /

+0.0389 (+4.89%)

, SPCE

Virgin Galactic

$22.25 /

+0.65 (+3.01%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: BigCommerce Holdings (BIGC) 38.92% +0.44, Canopy Growth (CGC) 2.36% +0.44, Microvision (MVIS) 51.58% +0.41, Trillium Therapeutics (TRIL) 0.71% +0.33, Blue Apron (APRN) 11.65% +0.32, Neptune Technologies (NEPT) 42.55% +0.28, Aphria (APHA) 2.11% +0.24, Hexo Corp (HEXO) 22.61% +0.24, Acorda Therapeutics (ACOR) 24.10% +0.23, and Virgin Galactic (SPCE) 15.41% +0.21.

ShowHide Related Items >><<
TRIL Trillium Therapeutics
$15.50 /

+1.44 (+10.24%)

SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

NEPT Neptune Wellness
$1.86 /

-0.01 (-0.53%)

MVIS MicroVision
$1.85 /

-0.005 (-0.27%)

HEXO Hexo
$0.74 /

-0.0002 (-0.03%)

CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

BIGC BigCommerce
$66.87 /

-6.3 (-8.61%)

APRN Blue Apron
$5.58 /

+0.015 (+0.27%)

APHA Aphria
$5.68 /

+0.255 (+4.70%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

BIGC BigCommerce
$66.87 /

-6.3 (-8.61%)

11/16/20 Truist
BigCommerce upgraded to Buy from Hold at Truist
11/16/20 Stifel
BigCommerce initiated with a Buy at Stifel
11/16/20 Truist
BigCommerce upgraded to Buy from Hold at Truist
11/13/20 Citi
Citi starts BigCommerce with Sell rating, $65 price target
CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

11/16/20 Jefferies
Canopy Growth price target raised to $21.10 from $16 at Jefferies
11/11/20 CIBC
Canopy Growth price target raised to C$32 from C$25 at CIBC
11/10/20 Canaccord
Canopy Growth price target raised to C$25 from C$22 at Canaccord
08/31/20 Roth Capital
Roth Capital believes MORE Act will not pass in 2020
MVIS MicroVision
$1.85 /

-0.005 (-0.27%)

05/06/20 Craig-Hallum
MicroVision rise driven by Microsoft speculation, says Craig-Hallum
02/26/20 Craig-Hallum
MicroVision downgraded to Hold from Buy at Craig-Hallum
02/26/20 H.C. Wainwright
MicroVision downgraded to Neutral from Buy at H.C. Wainwright
02/26/20 Ladenburg
Ladenburg downgrades MicroVision to Neutral on lost contract
TRIL Trillium Therapeutics
$15.50 /

+1.44 (+10.24%)

11/04/20 Cowen
Trillium ASH abstracts provide 'minimal updates', says Cowen
10/12/20 Evercore ISI
Trillium Therapeutics initiated with an Outperform at Evercore ISI
10/05/20 Piper Sandler
Patent fight likely to weigh on ALX Oncology shares NT, says Piper Sandler
10/01/20 Cowen
Trillium strengthens position with CD47 patent news, says Cowen
APRN Blue Apron
$5.58 /

+0.015 (+0.27%)

10/30/20 Canaccord
Blue Apron price target lowered to $14 from $18 at Canaccord
07/30/20 Canaccord
Canaccord upgrades Blue Apron as growth returns
07/30/20 Canaccord
Blue Apron upgraded to Buy from Hold at Canaccord
02/20/20 Truist
Blue Apron price target lowered to $5 from $8 at SunTrust
NEPT Neptune Wellness
$1.86 /

-0.01 (-0.53%)

08/27/20 Alliance Global Partners
Neptune Wellness deal shows ability to succeed in traditonal category, says AGP
08/07/20
Fly Intel: Top analyst initiations
08/07/20 Alliance Global Partners
Neptune Wellness initiated with a Buy at Alliance Global Partners
01/31/20 Cowen
Neptune Wellness initiated with a Market Perform at Cowen
APHA Aphria
$5.68 /

+0.255 (+4.70%)

11/06/20 CIBC
Aphria price target raised to C$9 from C$8 at CIBC
10/16/20 CIBC
Aphria price target raised to C$8 from C$7.50 at CIBC
10/16/20 Cantor Fitzgerald
Aphria price target lowered to C$11.75 from C$15.50 at Cantor Fitzgerald
10/05/20 Cantor Fitzgerald
Aphria price target raised to C$15.50 from C$12.50 at Cantor Fitzgerald
HEXO Hexo
$0.74 /

-0.0002 (-0.03%)

11/02/20 Canaccord
Hexo price target lowered to C$1 from C$1.50 at Canaccord
10/30/20 Alliance Global Partners
Hexo price target lowered to C$1.75 from C$2.50 at Alliance Global Partners
08/18/20 CIBC
Hexo price target lowered to C$0.90 from C$1.00 at CIBC
07/22/20 Cantor Fitzgerald
Hexo upgraded at Cantor Fitzgerald on improving industry, company trends
ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

10/23/20
Fly Intel: Pre-market Movers
10/23/20 Goldman Sachs
Virgin Galactic initiated with a Neutral at Goldman Sachs
09/28/20
Fly Intel: Top five analyst initiations
09/28/20 Susquehanna
Susquehanna starts Virgin Galactic with Positive rating, $20 price target
TRIL Trillium Therapeutics
$15.50 /

+1.44 (+10.24%)

SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

HEXO Hexo
$0.74 /

-0.0002 (-0.03%)

CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

BIGC BigCommerce
$66.87 /

-6.3 (-8.61%)

APRN Blue Apron
$5.58 /

+0.015 (+0.27%)

APHA Aphria
$5.68 /

+0.255 (+4.70%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

  • 13
    Nov
  • 11
    Sep
  • 06
    Aug
  • 06
    Aug
  • 05
    Aug
  • 03
    Jun
  • 20
    May
  • 19
    May
  • 23
    Jan
SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

MVIS MicroVision
$1.85 /

-0.005 (-0.27%)

CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

TRIL Trillium Therapeutics
$15.50 /

+1.44 (+10.24%)

SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

NEPT Neptune Wellness
$1.86 /

-0.01 (-0.53%)

MVIS MicroVision
$1.85 /

-0.005 (-0.27%)

HEXO Hexo
$0.74 /

-0.0002 (-0.03%)

CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

BIGC BigCommerce
$66.87 /

-6.3 (-8.61%)

APRN Blue Apron
$5.58 /

+0.015 (+0.27%)

APHA Aphria
$5.68 /

+0.255 (+4.70%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

TRIL Trillium Therapeutics
$15.50 /

+1.44 (+10.24%)

SPCE Virgin Galactic
$22.25 /

+0.65 (+3.01%)

NEPT Neptune Wellness
$1.86 /

-0.01 (-0.53%)

MVIS MicroVision
$1.85 /

-0.005 (-0.27%)

HEXO Hexo
$0.74 /

-0.0002 (-0.03%)

CGC Canopy Growth
$24.43 /

+0.61 (+2.56%)

BIGC BigCommerce
$66.87 /

-6.3 (-8.61%)

APRN Blue Apron
$5.58 /

+0.015 (+0.27%)

APHA Aphria
$5.68 /

+0.255 (+4.70%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

Hot Stocks
Athersys appoints Katherine Kalin, Jane Wasman, Baiju Shah to board » 06:12
11/16/20
11/16
06:12
11/16/20
06:12
ATHX

Athersys

$1.75 /

-0.14 (-7.43%)

, ACOR

Acorda Therapeutics

$0.83 /

+0.0389 (+4.89%)

Athersys (ATHX) announced…

Athersys (ATHX) announced that it has appointed Katherine Kalin, Jane Wasman and Baiju Shah to its board of directors. The group of professionals will help lead the company as it prepares for potential commercialization of its investigational cell therapy, MultiStem. In addition, Dr. Lee Babiss, a committed director since 2010, has announced his retirement and has stepped down from the board. Kalin, most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Wasman served as President, International & General Counsel and Corporate Secretary of Acorda Therapeutics (ACOR), a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. Shah serves as a Senior Fellow for Innovation at the Cleveland Foundation and a Senior Advisor to FasterCures, a Center of the Milken Institute.

ShowHide Related Items >><<
ATHX Athersys
$1.75 /

-0.14 (-7.43%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

ATHX Athersys
$1.75 /

-0.14 (-7.43%)

06/25/20 BofA
Athersys initiated with a Buy at BofA
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

ATHX Athersys
$1.75 /

-0.14 (-7.43%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

  • 16
    Apr
ATHX Athersys
$1.75 /

-0.14 (-7.43%)

ATHX Athersys
$1.75 /

-0.14 (-7.43%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

ATHX Athersys
$1.75 /

-0.14 (-7.43%)

ACOR Acorda Therapeutics
$0.83 /

+0.0389 (+4.89%)

Options
Largest borrow rate increases among liquid names » 08:45
11/09/20
11/09
08:45
11/09/20
08:45
SPI

SPI Energy

$7.83 /

-0.22 (-2.73%)

, MITT

AG Mortgage

$2.70 /

-0.1 (-3.57%)

, DDS

Dillard's

$45.66 /

-0.14 (-0.31%)

, APHA

Aphria

$5.51 /

+0.06 (+1.10%)

, SRNE

Sorrento Therapeutics

$7.00 /

-0.14 (-1.96%)

, GNUS

Genius Brands

$1.05 /

-0.025 (-2.33%)

, ACOR

Acorda Therapeutics

$0.80 /

-0.0376 (-4.47%)

, HUYA

Huya

$21.99 /

-0.72 (-3.17%)

, KNDI

Kandi Technologies

$9.42 /

+0.52 (+5.84%)

, ATHX

Athersys

$1.77 /

-0.05 (-2.75%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: SPI Energy (SPI) 81.41% +40.70, AG Mortgage (MITT) 13.21% +3.67, Dillard's (DDS) 59.75% +2.40, Aphria (APHA) 3.12% +1.68, Sorrento Therapeutics (SRNE) 28.71% +1.56, Genius Brands (GNUS) 10.25% +1.18, Acorda Therapeutics (ACOR) 27.93% +0.72, HUYA (HUYA) 3.47% +0.69, Kandi Technologies (KNDI) 13.55% +0.68, and Athersys (ATHX) 1.37% +0.54.

ShowHide Related Items >><<
SRNE Sorrento Therapeutics
$7.00 /

-0.14 (-1.96%)

SPI SPI Energy
$7.83 /

-0.22 (-2.73%)

MITT AG Mortgage
$2.70 /

-0.1 (-3.57%)

KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

HUYA Huya
$21.99 /

-0.72 (-3.17%)

GNUS Genius Brands
$1.05 /

-0.025 (-2.33%)

DDS Dillard's
$45.66 /

-0.14 (-0.31%)

ATHX Athersys
$1.77 /

-0.05 (-2.75%)

APHA Aphria
$5.51 /

+0.06 (+1.10%)

ACOR Acorda Therapeutics
$0.80 /

-0.0376 (-4.47%)

SPI SPI Energy
$7.83 /

-0.22 (-2.73%)

MITT AG Mortgage
$2.70 /

-0.1 (-3.57%)

05/26/20 Credit Suisse
AG Mortgage downgraded to Underperform from Neutral at Credit Suisse
DDS Dillard's
$45.66 /

-0.14 (-0.31%)

10/12/20 Wedbush
Dillard's price target raised to $46 from $30 at Wedbush
08/14/20 Wedbush
Dillard's Q2 EPS a positive surprise, says Wedbush
08/03/20 Wedbush
Dillard's price target raised to $26 from $19 at Wedbush
05/15/20 JPMorgan
Dillard's price target lowered to $23 from $32 at JPMorgan
APHA Aphria
$5.51 /

+0.06 (+1.10%)

11/06/20 CIBC
Aphria price target raised to C$9 from C$8 at CIBC
10/16/20 CIBC
Aphria price target raised to C$8 from C$7.50 at CIBC
10/16/20 Cantor Fitzgerald
Aphria price target lowered to C$11.75 from C$15.50 at Cantor Fitzgerald
10/05/20 Cantor Fitzgerald
Aphria price target raised to C$15.50 from C$12.50 at Cantor Fitzgerald
SRNE Sorrento Therapeutics
$7.00 /

-0.14 (-1.96%)

07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
07/20/20 Dawson James
Sorrento antibody cocktail effort could move quickly, says Dawson James
05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
GNUS Genius Brands
$1.05 /

-0.025 (-2.33%)

ACOR Acorda Therapeutics
$0.80 /

-0.0376 (-4.47%)

HUYA Huya
$21.99 /

-0.72 (-3.17%)

11/05/20 China Renaissance
DouYu downgraded to Hold from Buy at China Renaissance
11/05/20 China Renaissance
Huya downgraded to Hold from Buy at China Renaissance
10/15/20 JPMorgan
Huya price target lowered to $23 from $27 at JPMorgan
07/21/20 JPMorgan
Huya downgraded to Neutral from Overweight at JPMorgan
KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

ATHX Athersys
$1.77 /

-0.05 (-2.75%)

06/25/20 BofA
Athersys initiated with a Buy at BofA
06/25/20 BofA
Athersys initiated with a Buy at BofA
06/22/20 Dawson James
Channel checks dispute NY Times' COVID contention, says Dawson James
04/23/20 SMBC Nikko
Athersys initiated with an Outperform at SMBC Nikko
MITT AG Mortgage
$2.70 /

-0.1 (-3.57%)

KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

HUYA Huya
$21.99 /

-0.72 (-3.17%)

DDS Dillard's
$45.66 /

-0.14 (-0.31%)

ATHX Athersys
$1.77 /

-0.05 (-2.75%)

APHA Aphria
$5.51 /

+0.06 (+1.10%)

ACOR Acorda Therapeutics
$0.80 /

-0.0376 (-4.47%)

  • 01
    Oct
  • 16
    Apr
SRNE Sorrento Therapeutics
$7.00 /

-0.14 (-1.96%)

KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

GNUS Genius Brands
$1.05 /

-0.025 (-2.33%)

ATHX Athersys
$1.77 /

-0.05 (-2.75%)

APHA Aphria
$5.51 /

+0.06 (+1.10%)

SRNE Sorrento Therapeutics
$7.00 /

-0.14 (-1.96%)

SPI SPI Energy
$7.83 /

-0.22 (-2.73%)

MITT AG Mortgage
$2.70 /

-0.1 (-3.57%)

KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

HUYA Huya
$21.99 /

-0.72 (-3.17%)

GNUS Genius Brands
$1.05 /

-0.025 (-2.33%)

DDS Dillard's
$45.66 /

-0.14 (-0.31%)

ATHX Athersys
$1.77 /

-0.05 (-2.75%)

APHA Aphria
$5.51 /

+0.06 (+1.10%)

ACOR Acorda Therapeutics
$0.80 /

-0.0376 (-4.47%)

SRNE Sorrento Therapeutics
$7.00 /

-0.14 (-1.96%)

SPI SPI Energy
$7.83 /

-0.22 (-2.73%)

MITT AG Mortgage
$2.70 /

-0.1 (-3.57%)

KNDI Kandi Technologies
$9.42 /

+0.52 (+5.84%)

HUYA Huya
$21.99 /

-0.72 (-3.17%)

GNUS Genius Brands
$1.05 /

-0.025 (-2.33%)

DDS Dillard's
$45.66 /

-0.14 (-0.31%)

APHA Aphria
$5.51 /

+0.06 (+1.10%)

ACOR Acorda Therapeutics
$0.80 /

-0.0376 (-4.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.